Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meds Apotek AB (publ)OSTO:MEDS +18.31%11 EBITDA Margin % is 3.37% as of Jun. 2026, which is 107% above its 10-year median of 1.63. GuruFocus rates OSTO:MEDS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,129 Retail - Cyclical companies, Meds Apotek AB (publ) ranks worse than 76.62% on this metric.
Meds Apotek AB (publ) (OSTO:MEDS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Meds Apotek AB (publ) EBITDA Margin % Related Terms
Meds Apotek AB (publ) EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Meds Apotek AB (publ)'s EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MEDS vs AMZN, BABA, PDD: EBITDA Margin % Comparison
For the Internet Retail subindustry, Meds Apotek AB (publ)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meds Apotek AB (publ) EBITDA Margin % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Meds Apotek AB (publ)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Meds Apotek AB (publ)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meds Apotek AB (publ) (OSTO:MEDS) has a EBITDA Margin % of 3.37% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Meds Apotek AB (publ) and its competitors. This is 107% above median its historical median of 1.63. According to the industry distribution chart, Meds Apotek AB (publ) ranks #865 out of 1129 companies in the Retail - Cyclical industry, placing it in the top 76.6%.
Is Meds Apotek AB (publ)'s EBITDA Margin % too high?
Meds Apotek AB (publ)'s current EBITDA Margin % of 3.37% is 107% above median its 10-year median of 1.63. The Retail - Cyclical industry median EBITDA Margin % is 7.45. Meds Apotek AB (publ)'s value of 3.37% is 54.8% below this industry median. Based on the distribution chart, Meds Apotek AB (publ) ranks #865 out of 1129 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Meds Apotek AB (publ) has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Meds Apotek AB (publ)'s EBITDA Margin % compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Meds Apotek AB (publ) ranks #865 out of 1129 companies for EBITDA Margin %. This places Meds Apotek AB (publ) in the lower half of its industry. The industry median EBITDA Margin % is 7.45. Meds Apotek AB (publ)'s value of 3.37% is 54.8% below this benchmark. While the company's 10-year median is 1.63 vs. the industry median of 7.45, Meds Apotek AB (publ) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Retail - Cyclical company?
The median EBITDA Margin % among Retail - Cyclical companies is 7.45, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meds Apotek AB (publ)'s current EBITDA Margin % of 3.37% is 54.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Meds Apotek AB (publ) and its competitors. For the Retail - Cyclical industry, the median EBITDA Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meds Apotek AB (publ)'s current EBITDA Margin % is 3.37%, which is 107% above median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meds Apotek AB (publ) stock overvalued right now?
Meds Apotek AB (publ) (OSTO:MEDS) has a current EBITDA Margin % of 3.37%. The current EBITDA Margin % is 3.37%, which is 107% above median its 10-year median of 1.63 and 54.8% below the Retail - Cyclical industry median of 7.45. Meds Apotek AB (publ)'s overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Meds Apotek AB (publ) (OSTO:MEDS), the current EBITDA Margin % is 3.37% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Meds Apotek AB (publ) is a full-scale online pharmacy that sells prescription and over-the-counter medicines with permission from the Medical Products Agency, the Swedish Food Agency and the E-Health Agency. The company's pharmacy products include everything in health, well-being, dietary supplements, beauty products, children's products, fitness products, food and drink and home & household products.
11GF Score
Get the complete analysis for OSTO:MEDS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MEDS has been successfully added to your 
